However, recent data indicate that activin A signalling, and hence potentially FST, may play stage‐specific roles in prostate cancer, with non‐canonical activin A signalling maintaining epithelial quiescence in the normal prostate [45] but activin A positively regulating metastasis in pre‐clinical models and associating with poor prognosis in prostate cancer patients [46]. The gene discussed is FST; the disease is prostate carcinoma.